What did @jasonposton actually say?
Jason Poston told his 123K viewers that BPC-157 is now available in oral pill form, compounded alongside a peptide called KPV, which he described as "the newest anti-inflammatory peptide." He listed specific conditions KPV may help with, including eczema, acne, ulcerative colitis, and general wound healing, and framed the combination as getting "two bang for your buck." He also said BPC-157 has "always been an injectable form," implying oral delivery is a recent development worth noticing.
The claims are a mix of things that have real scientific support, things that are technically true but missing important context, and at least one framing that stretches ahead of what the evidence actually shows. Let's take them apart.
Does the science back this up?
Partially, yes, but the research base is thinner than the confident delivery suggests. BPC-157 has demonstrated anti-inflammatory and wound-healing effects in animal models, and there is a reasonable mechanistic rationale for oral delivery because the peptide appears stable in gastric acid. KPV, a tripeptide derived from alpha-MSH, does have legitimate preclinical data behind it, particularly for gut inflammation.
On BPC-157 oral bioavailability: studies in rodent models, including work by Sikiric et al. published repeatedly in Current Pharmaceutical Design, suggest oral BPC-157 can produce systemic effects. However, no peer-reviewed human pharmacokinetic data confirms equivalent bioavailability to subcutaneous injection in people. That gap matters enormously for dosing and efficacy assumptions.
On KPV: a 2022 study by Viennois et al. in the Journal of Crohn's and Colitis showed KPV-loaded nanoparticles reduced inflammation in mouse models of colitis. A 2006 paper by Dalmasso et al. in the same journal found KPV reduced inflammatory cytokines in intestinal epithelial cells. These are real findings, but they are primarily in vitro and animal data. Human clinical trials on KPV are essentially absent from the published literature as of 2024.
What did they get wrong (or right)?
Saying BPC-157 has "always been an injectable form" is not quite accurate. Oral and sublingual BPC-157 formulations have been studied and discussed in research and compounding contexts for years. This framing makes the pill version sound more novel than it is, which appears designed to build excitement rather than inform.
Calling KPV "the newest anti-inflammatory peptide" is marketing language, not a scientific designation. KPV has been in the research literature since at least the early 2000s. Newest compared to what is doing a lot of work in that sentence.
Where Poston deserves credit: he correctly identifies the core mechanisms, anti-inflammatory action and wound healing, that KPV research actually points toward. He does not claim it is FDA-approved or make specific dosing recommendations. The ulcerative colitis reference has at least some preclinical grounding. He is not entirely making things up, he is just presenting an early-stage research story as if the clinical chapter has already been written.
What should you actually know?
Compounded peptides like this combination are not FDA-approved drugs. They are prepared by compounding pharmacies under prescriber supervision, which means quality, purity, and dosing consistency vary by vendor. If you are considering this, the conversation starts with a licensed clinician, not an Instagram comments section.
The combination of KPV and BPC-157 in a single oral formulation is an interesting direction in peptide compounding, but calling it validated is a stretch. There are no published human trials on this specific combination. The individual components have encouraging preclinical profiles, particularly for gut-related inflammation, but efficacy in humans at compounded oral doses remains unproven.
For people with diagnosed conditions like ulcerative colitis, eczema, or chronic wounds, existing standard-of-care treatments have actual clinical trial data behind them. A peptide compound might be an adjunct worth discussing with your doctor, but framing it as a treatment for those diseases, without that conversation, is not a responsible takeaway from a 60-second video.
The bottom line on this video
Poston is not spreading pure fiction, but he is presenting speculative science with a confidence level the data does not support yet. The peptide combination is real, the compounding is legal in the right clinical context, and some of the underlying biology is legitimate. But "helpful in the treatment of ulcerative colitis" based on mouse studies and cell culture data is not the same as a proven therapy. Viewers should treat this as a primer on what researchers are exploring, not a treatment recommendation.